Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
16 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
16
Trials led
0
Ongoing
7,851
Total enrollment
0
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
1
Phase 3
14
Phase 4
1
Trials by status
Completed
16
Trials led
TrialEligibility highlightPhaseStatusEnrollment
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive ImpairmentAge ≥50Ph 3Completed1,063
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive ImpairmentAge ≥50Ph 3Completed974
Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulationmild-to-moderate ADPh 3Completed973
A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive ImpairmentAge ≥50Ph 3Completed724
A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's DiseaseAlzheimer's diseasePh 3Completed653
A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's DiseaseAlzheimer's diseasePh 3Completed636
A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed DementiaMultiple dementia etiologiesPh 3Completed593
Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's DiseaseAlzheimer's diseasePh 3Completed554
Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's DiseaseMMSE 5-23Ph 3Completed473
A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's DiseaseAlzheimer's diseasePh 3Completed387
A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular DementiaVascular dementiaPh 3Completed254
A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.Alzheimer's diseasePh 3Completed139
Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's DiseaseAlzheimer's diseasePh 3Completed83